Core Viewpoint - A class action lawsuit has been filed against Fortrea Holdings Inc. for alleged violations of the Securities Exchange Act of 1934, specifically regarding misrepresentations about the company's EBITDA targets for 2025 [1][2]. Group 1: Lawsuit Details - The complaint was filed in the United States District Court for the Southern District of New York on behalf of investors who purchased Fortrea securities between July 3, 2023, and February 28, 2025 [1]. - The lawsuit alleges that the company and certain senior officers made misrepresentations concerning the company's financial targets [2]. Group 2: Legal Participation - Investors who wish to serve as lead plaintiffs must file necessary documents by August 1, 2025, although participation as a lead plaintiff is not required to share in any potential recovery [3]. - All legal representation in this case is on a contingency fee basis, meaning shareholders will not incur any fees or expenses [3]. Group 3: Firm Background - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has represented both individual investors and large public and private pension funds [4]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [4].

Core Viewpoint - Fortrea Holdings Inc. is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its financial projections and business model [3][4]. Allegations - The complaint claims that Fortrea overestimated revenue contributions from its long-term projects, known as the Pre-Spin Projects, for the year 2025 [3]. - It is alleged that the company overstated potential cost savings from exiting transition services agreements [3]. - The previously announced EBITDA targets for 2025 were inflated as a result of these misstatements [3]. - The viability of Fortrea's post-spin-off business model and its financial prospects were also overstated [3]. - Overall, the company's public statements were materially false and misleading throughout the relevant period [3]. Class Action Details - The class period for the lawsuit is from July 3, 2023, to February 28, 2025 [3]. - Shareholders are encouraged to register for the class action by the deadline of August 1, 2025 [4]. - Participants will be enrolled in a portfolio monitoring software to receive updates on the case [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Fortrea Holdings Inc. (NASDAQ: FTRE) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Fortrea you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/fortrea-holdings-inc-class-action-lawsuit. Investors have until August 1, 2025, to ask th ...

Market Overview - The current Fortrea total addressable market size is over approximately $35 billion[8] - The Pharma & Biotech clinical development spend is over approximately $100 billion[8] - The industry projects a 6-9% long-term CRO market growth and a 3-5% near-term CRO market growth[8] - The industry projects an approximate 4% annual increase in CRO outsourcing rate[8] - Total Pharma R&D spend is projected to increase from $262 billion in 2023E to $302 billion in 2028E[8] Fortrea's Strategy and Operations - Fortrea was formed as an independent, publicly-listed company on July 1, 2023[12] - Fortrea conducts operations in over 90 countries[16] - More than one third of TSAs were exited by December 31st, 2023, with the remainder targeted for exit by December 31st, 2024[27] Quality and Compliance - Fortrea has conducted 797 customer audits and 391 regulatory inspections since 2020[32] - Fortrea has over 129 QA professionals globally, with over 42% having 5+ years tenure with Fortrea[32]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Fortrea Holdings, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on August 1, 2025, and the potential for compensation without out-of-pocket costs [1][2]. Group 1: Class Action Details - Investors who bought Fortrea securities between July 3, 2023, and February 28, 2025, may be eligible to join a class action lawsuit [1][2]. - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to represent other class members [2][6]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. Group 3: Allegations Against Fortrea - The lawsuit alleges that Fortrea made false and misleading statements regarding its revenue projections and cost savings, leading to inflated EBITDA targets for 2025 [4]. - The claims suggest that Fortrea's business model and financial prospects were overstated, resulting in investor damages when the true information became public [4].

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Fortrea Holdings Inc. ("Fortrea Holdings Inc." or the "Company") (NASDAQ: FTRE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fortrea Holdings Inc. investors who were adversely affected by alleged securities fraud between July 3, 2023 and February 28, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/psl ...

LOS ANGELES, June 16, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 1, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Fortrea Holdings Inc. (“Fortrea” or the “Company”) (NASDAQ: FTRE) securities between July 3, 2023 and February 28, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR FORTREA INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS T ...

NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Fortrea Holdings Inc. (NASDAQ: FTRE) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Fortrea you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/fortrea-holdings-inc-class-action-lawsuit. Investors have until August 1, 2025, to ask th ...

NEW YORK, June 16, 2025 /PRNewswire/ --The Gross Law Firm issues the following notice to shareholders of Fortrea Holdings Inc. (NASDAQ: FTRE).Shareholders who purchased shares of FTRE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/fortrea-holdings-inc-loss-submission-form/?id=152955&from=4CLASS PERIOD: July 3, 202 ...

Core Viewpoint - Fortrea Holdings Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding its financial performance and business model following its spin-off from Labcorp Holdings Inc. [1][3] Company Overview - Fortrea is a global clinical research organization (CRO) that provides development solutions for biopharmaceutical products and medical devices [2]. - The company was spun off from Labcorp in June 2023, with ongoing long-term projects at the time of the spin-off [2]. Allegations of the Lawsuit - The lawsuit claims that Fortrea overestimated revenue contributions from pre-spin projects, overstated cost savings from exiting transition services agreements (TSAs), and inflated its EBITDA targets for 2025 [3]. - Specific allegations include: - Overestimation of revenue from pre-spin projects [3]. - Overstatement of cost savings from exiting TSAs [3]. - Inflated EBITDA targets for 2025 [3]. - Overstated viability of Fortrea's post-spin business model [3]. Impact of Analyst Reports - On September 25, 2024, Jefferies downgraded Fortrea from buy to hold, citing weaknesses in its business model and a lack of material cost savings from exiting TSAs, leading to a stock price drop of over 12% [4]. - On December 6, 2024, Baird Equity Research downgraded Fortrea to neutral, resulting in an 8% decline in stock price after the company canceled two scheduled conferences [5]. Financial Performance Disclosure - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA projections for 2025 were not aligned with prior expectations, revealing that pre-spin projects were underperforming and negatively impacting financial performance [6]. - Following this announcement, Fortrea's stock price fell by more than 25% [6].